Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
AssigneesThe Wistar Institute of Anatomy and Biology, The Trustees of the University of Pennsylvania
InventorsHildegund C. J. Ertl, James M. Wilson
Life of this patent
Estimating the term…
Abstract
A replication defective recombinant adenovirus is provided which contains a complete deletion of its E1 gene and at least a partial deletion of its E3 gene, said virus containing in the site of the E1 deletion a sequence comprising a non-adenovirus promoter directing the replication and expression of DNA encoding a heterologous protein from a disease-causing agent, which, when administered to a mammal in said recombinant virus, elicits a substantially complete protective immune response against the agent. Pharmaceutical and veterinary products containing the recombinant adenovirus are provided.
Claims6
A method of inducing an immune response against human papilloma virus comprising:
- administering to a mammalian subject a sufficient amount of a recombinant adenovirus comprising a human serotype 5 adenovirus containing a complete deletion of its E1 gene and at least a functional deletion of its E3 gene, and, in the site of the E1 gene deletion, a sequence comprising a cytomegalovirus promoter directing the replication and expression of DNA encoding a human papilloma virus protein, which when administered to the subject in said recombinant virus, elicits a protective immune response against human papilloma virus.
Dependencies are inferred from the claim text.